Platelet-rich plasma injections. Bone marrow aspirate concentrate. Stem cell therapies. If you handle workers’ compensation claims involving musculoskeletal injuries, you have almost certainly seen these treatments — collectively known as orthobiologics — appearing on treatment plans and medical bills with increasing frequency. Patients are now asking for PRP by name. Treating physicians are offering it as an alternative to surgery. And the bills are landing on adjusters’ desks with price tags that can run from several hundred to several thousand dollars per injection.
There is just one problem: the clinical evidence supporting many of these treatments remains thin, inconsistent, and — according to a growing chorus of orthopedic leaders — insufficient to justify the pace at which they are being adopted. A Healio editorial published August 6, 2026, titled “Separate Science from Hope,” put the issue in stark terms: “Few areas of orthopedic practice have grown faster and with thinner evidence than orthobiologics.”
The editorial was prompted by a major institutional response to the evidence gap. In December 2025, the American Academy of Orthopaedic Surgeons (AAOS) announced the creation of the AAOS Orthobiologics Registry, developed in collaboration with the American Orthopaedic Society for Sports Medicine (AOSSM), the Arthroscopy Association of North America, and the Biologic Association. The registry’s stated mission, as its leadership has framed it, is to separate science from hope — to build the kind of rigorous, real-world outcomes data that the existing PRP and orthobiologics literature largely lacks.
Here are some basic terms to understand:
– – Orthobiologics is an umbrella term for biological substances used to promote healing of musculoskeletal tissues — bones, muscles, tendons, and ligaments. The most commonly encountered treatments include:
– – Platelet-rich plasma (PRP), in which a patient’s own blood is drawn, centrifuged to concentrate the platelets and their associated growth factors, and injected into an injured joint or tendon. The theory is that the concentrated growth factors accelerate tissue repair.
– – Bone marrow aspirate concentrate (BMAC), in which marrow is drawn from the patient’s pelvis, concentrated, and injected into the treatment site. BMAC contains mesenchymal stem cells that have the theoretical potential to differentiate into cartilage, bone, or tendon tissue.
– – Stromal vascular fraction (SVF) and adipose-derived stem cells, harvested from the patient’s own fat tissue.
These treatments are appealing in concept. They use the patient’s own biological material, they are minimally invasive compared to surgery, and they promise regeneration rather than mere symptom management. But “appealing in concept” and “supported by clinical evidence” are not the same thing. The clinical evidence for orthobiologics is characterized by three persistent weaknesses that are directly relevant to workers’ comp claims handling.
– – First, there is no standardization. PRP is not a single product — it is a category. The concentration of platelets, the presence or absence of white blood cells (leukocyte-rich versus leukocyte-poor), the activation method, and the volume injected all vary widely between providers and even between injections at the same clinic. Two patients who both receive “PRP for knee osteoarthritis” may be getting fundamentally different treatments. This heterogeneity makes it extremely difficult to draw reliable conclusions from the published literature, because studies using different preparation protocols are being pooled together as though they were studying the same intervention.
– – Second, the high-quality evidence that does exist shows modest and often short-lived benefits. A comprehensive narrative review published in the Journal of Clinical Medicine in June 2025 found that PRP injections — particularly leukocyte-poor formulations — demonstrated some pain relief and functional improvement for mild to moderate knee osteoarthritis compared to hyaluronic acid and corticosteroids. But the improvements were inconsistent across studies, follow-up periods were generally short, and the clinical significance of the measured differences was debatable. As a Healio September 2025 editorial on orthobiologics noted, “when studied through the lens of high-level clinical evidence, the picture is less convincing of the clinical benefit.”
– – Third, and critically for workers’ comp, PRP is not FDA-approved as a drug or biologic therapy. The FDA regulates the centrifuge devices used to prepare PRP, but it does not evaluate or approve the PRP treatment itself for any specific clinical indication. Physicians use PRP off-label, meaning the safety and efficacy for any given condition have not been established through the FDA’s standard approval process. This regulatory gap creates a challenging situation for utilization review teams and bill review departments tasked with determining whether a PRP injection meets medical necessity criteria.
The AAOS Orthobiologics Registry is designed to address these evidence gaps by collecting standardized, real-world data on orthobiologic treatments as they are actually used in clinical practice, tracking preparation protocols, patient characteristics, treatment indications, and outcomes over time. The Healio editorial noted that the registry’s published attributes are more rigorous than most existing PRP literature.
This matters because the registry could, for the first time, produce the kind of large-scale, standardized outcomes data that would allow the medical community — and, by extension, workers’ comp payers, treatment guideline panels, and utilization review organizations — to determine which orthobiologic treatments work, for which conditions, using which preparation methods, and for which patients. That data does not exist today in any reliable form.
The AOSSM reinforced this priority at its 2026 Annual Meeting in Seattle (July 8-11), where the AAOS Biologics Summit returned as a full-day pre-meeting workshop co-chaired by leading researchers in the field. The summit’s explicit focus was on how biologics are transforming sports medicine — and where the evidence needs to catch up.
PRP injections typically range from $500 to $2,000 per treatment, and many protocols call for a series of two to three injections. BMAC procedures can cost significantly more. These are out-of-pocket costs in many contexts because most health insurers do not cover PRP, but in workers’ comp, where the employer or insurer is responsible for reasonable and necessary medical treatment, the question of coverage cannot be avoided.
Unlike most medical treatments, PRP and stem cell therapies are heavily marketed directly to patients. Injured workers may arrive at their treating physician’s office requesting PRP by name, based on advertising or word of mouth. This consumer-driven demand creates pressure on physicians to offer the treatment regardless of the strength of the evidence for the specific condition.
As the AAOS Orthobiologics Registry begins producing data, that data will likely influence treatment guideline updates, utilization review standards, and medical necessity determinations. Claims professionals should monitor registry publications and be prepared for the possibility that the data could cut either way — validating PRP for some conditions while undermining it for others.